This site is intended for healthcare professionals
Login
Register
Medical Education
Specialty
Drugs
News
Congresses
Search
Menu
Medical Education
Specialty
Drugs
News
Congresses
Home
/
Discontinued Drugs
/
New drug name(14)(16)(25)
Discontinued drug
New drug name(14)(16)(25)
Read time:
1 mins
Last updated:
21st Sep 2020
Share
Alternative approved drugs and related content
News
Blincyto + chemo boosts survival in pediatric B-ALL
3 mins
Drug news
ENERGIZE-T: Positive results for mitapivat in thalassemia
3 mins
Drug news
TEMPO-2: Positive results for tavapadon in early Parkinson's
3 mins
Drug news
KEYLYNK-001: Keytruda + chemo, Lynparza for BRCA ovarian cancer.
1 mins
Guideline
Systematic review-based guideline “Parkinson’s disease” of the German Society of Neurology: diagnostic use of transcranial sonography
1 mins
Guideline
Guideline “Parkinson’s disease” of the German Society of Neurology (Deutsche Gesellschaft für Neurologie): concepts of care
1 mins
Guideline
Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations - guideline “Parkinson’s disease” of the German Society of Neurology
1 mins
Guideline
German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson’s disease: new spotlights on diagnostic procedures and non-pharmacological interventions
1 mins
Guideline
Pharmacotherapy of motor symptoms in early and mid-stage Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology
1 mins
Guideline
Physical therapist management of Parkinson Disease: A clinical practice guideline from the American Physical Therapy Association
1 mins
Guideline
European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies
2 mins
Guideline
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023
1 mins
Drug news
Phase III data: ACCESS-1 trial of pozelimab + cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria
4 mins
Drug news
Longer term results from phase IIIASC4FIRST trial with Scemblix (asciminib) showing superior major molecular response (MMR) rates at week 96
1 mins
Guideline
Migraine treatment: Position paper of the French Headache Society
1 mins
Guideline
International Headache Society global practice recommendations for preventive pharmacological treatment of migraine
1 mins
Guideline
International Headache Society global practice recommendations for the acute pharmacological treatment of migraine
1 mins
Drug news
Long term data from ongoing X-TOLE open-label extension (OLE) study of azetukalner in patients with focal onset seizures.- Xenon Pharmaceuticals
4 mins
News
Results from phase III POD1UM-304 trial of Zynyz ( retifanlimab ) + chemotherapy in NSCLC.- Incyte Inc.
2 mins
Drug news
Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR- Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis- Daiichi Sankyo
2 mins
Top